Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122913 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02122913 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 75 participants.
The verdict
NCT02122913, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists.
Interventions
- DRUG Larotrectinib (Vitrakvi, BAY2757556)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-05-04 |
| Est. Completion | 2021-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122913
The ClinicalTrials.gov registry entry for NCT02122913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Larotrectinib (Vitrakvi, BAY2757556) is the first listed.
NCT02122913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02122913 about?
NCT02122913 is a clinical study titled "A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer". This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is...
What is the current status of trial NCT02122913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2014-05-04. Estimated completion is 2021-04-09.
What interventions are being tested in trial NCT02122913?
The interventions under investigation include: Larotrectinib (Vitrakvi, BAY2757556) (DRUG).
Who is sponsoring clinical trial NCT02122913?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.